Prima BioMed Ltd., of Sydney, Australia, said it started recruiting patients in its CANVAS (CANcer VAccine Study) Phase II/III trial in Europe to test CVac for the maintenance treatment of newly diagnosed, late-stage epithelial ovarian cancer in patients who achieve remission after optimal debulking surgery and standard first-line chemotherapy.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter